全文获取类型
收费全文 | 4046篇 |
免费 | 147篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 128篇 |
儿科学 | 126篇 |
妇产科学 | 157篇 |
基础医学 | 593篇 |
口腔科学 | 12篇 |
临床医学 | 229篇 |
内科学 | 994篇 |
皮肤病学 | 19篇 |
神经病学 | 496篇 |
特种医学 | 67篇 |
外科学 | 395篇 |
综合类 | 38篇 |
预防医学 | 203篇 |
眼科学 | 105篇 |
药学 | 428篇 |
中国医学 | 21篇 |
肿瘤学 | 203篇 |
出版年
2023年 | 11篇 |
2022年 | 55篇 |
2021年 | 110篇 |
2020年 | 43篇 |
2019年 | 70篇 |
2018年 | 78篇 |
2017年 | 59篇 |
2016年 | 59篇 |
2015年 | 88篇 |
2014年 | 115篇 |
2013年 | 138篇 |
2012年 | 262篇 |
2011年 | 274篇 |
2010年 | 152篇 |
2009年 | 106篇 |
2008年 | 246篇 |
2007年 | 315篇 |
2006年 | 314篇 |
2005年 | 319篇 |
2004年 | 341篇 |
2003年 | 327篇 |
2002年 | 244篇 |
2001年 | 22篇 |
2000年 | 14篇 |
1999年 | 22篇 |
1998年 | 23篇 |
1997年 | 33篇 |
1996年 | 22篇 |
1995年 | 23篇 |
1994年 | 16篇 |
1993年 | 16篇 |
1992年 | 14篇 |
1991年 | 9篇 |
1988年 | 11篇 |
1986年 | 12篇 |
1985年 | 9篇 |
1984年 | 21篇 |
1983年 | 19篇 |
1982年 | 16篇 |
1981年 | 11篇 |
1980年 | 8篇 |
1979年 | 10篇 |
1978年 | 10篇 |
1977年 | 10篇 |
1975年 | 12篇 |
1974年 | 11篇 |
1973年 | 8篇 |
1972年 | 7篇 |
1965年 | 15篇 |
1932年 | 9篇 |
排序方式: 共有4214条查询结果,搜索用时 500 毫秒
61.
Satoshi Uchiyama Federica Andreoni Claudia Zürcher Katrin Schilcher Miriam Ender Jerzy Madon Ulrich Matt Partho Ghosh Victor Nizet Reto A. Schuepbach Annelies S. Zinkernagel 《Journal of molecular medicine (Berlin, Germany)》2013,91(7):861-869
Group A Streptococcus (GAS) is a human pathogen causing a wide range of mild to severe and life-threatening diseases. The GAS M1 protein is a major virulence factor promoting GAS invasiveness and resistance to host innate immune clearance. M1 displays an irregular coiled-coil structure, including the B-repeats that bind fibrinogen. Previously, we found that B-repeat stabilisation generates an idealised version of M1 (M1*) characterised by decreased fibrinogen binding in vitro. To extend these findings based on a soluble truncated version of M1, we now studied the importance of the B-repeat coiled-coil irregularities in full length M1 and M1* expressed in live GAS and tested whether the modulation of M1–fibrinogen interactions would open up novel therapeutic approaches. We found that altering either the M1 structure on the GAS cell surface or removing its target host protein fibrinogen blunted GAS virulence. GAS expressing M1* showed an impaired ability to adhere to and to invade human endothelial cells, was more readily killed by whole blood or neutrophils and most importantly was less virulent in a murine necrotising fasciitis model. M1-mediated virulence of wild-type GAS was strictly dependent on the presence and concentration of fibrinogen complementing our finding that M1–fibrinogen interactions are crucial for GAS virulence. Consistently blocking M1–fibrinogen interactions by fragment D reduced GAS virulence in vitro and in vivo. This supports our conclusion that M1–fibrinogen interactions are crucial for GAS virulence and that interference may open up novel complementary treatment options for GAS infections caused by the leading invasive GAS strain M1. 相似文献
62.
Renata Zajączkowska Barbara Przewłocka Magdalena Kocot-Kępska Joanna Mika Wojciech Leppert Jerzy Wordliczek 《Pharmacological reports : PR》2018,70(4):812-820
Tapentadol is a centrally acting analgesic with a dual mode of action as a μ-opioid receptor (MOR) agonist and a noradrenaline reuptake inhibitor (NRI). It was initially approved by the US Food and Drug Administration in November 2008 for the treatment of moderate-to-severe acute pain in adult patients, and in August 2011, for chronic pain in an prolonged release form in the same population. Due to its limited protein binding capacity, the absence of active metabolites and significant microsomal enzyme induction or inhibition, tapentadol has a limited potential for drug–drug interactions. It appears to be well-tolerated and effective in the treatment of moderate-to severe acute and chronic pain. Owing to its dual mechanism of action, it is hypothesized to be good option in the treatment of both nociceptive and neuropathic pain. 相似文献
63.
64.
65.
66.
Philip N. Patsalos Jerzy P. Szaflarski Barry Gidal Kevan VanLandingham David Critchley Gilmour Morrison 《Epilepsia》2020,61(9):1854-1868
Highly purified cannabidiol (CBD) has demonstrated efficacy with an acceptable safety profile in patients with Lennox-Gastaut syndrome or Dravet syndrome in randomized, double-blind, add-on, controlled phase 3 trials. It is important to consider the possibility of drug-drug interactions (DDIs). Here, we review six trials of CBD (Epidiolex/Epidyolex; 100 mg/mL oral solution) in healthy volunteers or patients with epilepsy, which investigated potential interactions between CBD and enzymes involved in drug metabolism of common antiseizure drugs (ASDs). CBD did not affect CYP3A4 activity. Induction of CYP3A4 and CYP2C19 led to small reductions in exposure to CBD and its major metabolites. Inhibition of CYP3A4 activity did not affect CBD exposure and caused small increases in exposure to CBD metabolites. Inhibition of CYP2C19 activity led to a small increase in exposure to CBD and small decreases in exposure to CBD metabolites. One potentially clinically important DDI was identified: combination of CBD and clobazam (CLB) did not affect CBD or CLB exposure, but increased exposure to major metabolites of both compounds. Reduction of CLB dose may be considered if adverse reactions known to occur with CLB are experienced when it is coadministered with CBD. There was a small increase of exposure to stiripentol (STP) when coadministered with CBD. STP had no effect on CBD exposure but led to minor decreases in exposure to CBD metabolites. Combination of CBD and valproate (VPA) did not cause clinically important changes in the pharmacokinetics of either drug, or 2-propyl-4-pentenoic acid. Concomitant VPA caused small increases in exposure to CBD metabolites. Dose adjustments are not likely to be necessary when CBD is combined with STP or VPA. The safety results from these trials were consistent with the known safety profile of CBD. These trials indicate an overall low potential for DDIs between CBD and other ASDs, except for CLB. 相似文献
67.
Paweł Majak Dorota Jurałowicz Joanna Jerzyńska Katarzyna Smejda Włodzimierz Stelmach Iwona Stelmach 《Pulmonary pharmacology & therapeutics》2013,26(2):290-295
BackgroundThe remission of asthma, which is induced during specific immunotherapy (SIT) or appears spontaneously in children is not completely understood and predictors of this phenomenon are still undefined.ObjectiveTo assess CD4+CD25+Foxp3+ Treg cells and cytokine/proliferation response to allergen-specific stimulation of PBMC as predictors of steroid sparing effect of SIT and steroid dosage needs without SIT during 5 years of follow-up in asthmatic children.MethodsThis is a 5-year long study of 32 asthmatic children, sensitive only to house dust mite (HDM). Eighteen children who had completed 5 years of HDM SIT – SIT group, and 14 children without SIT as a control group were studied. All patients had baseline clinical/immunological assessment; before and after observation the minimum effective ICS dose was defined and lung function was measured.ResultsIn children from SIT group minimum effective ICS dose was reduced more than in children from control group (median reduction 65% vs. 0%; p < 0.001). Among patients in control group asthma severity was reduced after 5 years of observation in those who had at baseline higher TGF-beta1 and lower IL-13 answer to allergen stimulation of PBMC. Better response to 5 years immunotherapy was observed in those who had at baseline higher TGF-beta1 and lower proliferation answer to allergen stimulation of PBMC.ConclusionSimilar processes may decide on both, SIT-induced and spontaneously appearing, reduction in asthma severity. Immunotherapy was much more effective than pharmacotherapy in our study. IL-13 overproduction may impede reduction of disease severity in asthmatic children independently from TGF-beta pathway. 相似文献
68.
69.
Jerzy Falandysz 《journal of environmental science and health part c-environmental carcinogenesis & ecotoxicology reviews》2013,31(3):256-299
Selenium is vital to human health. This article is a compendium of virtually all the published data on total selenium concentrations, its distribution in fruitbody, bioconcentration factors, and chemical forms in wild-grown, cultivated, and selenium-enriched mushrooms worldwide. Of the 190 species reviewed (belonging to 21 families and 56 genera), most are considered edible, and a few selected data relate to inedible mushrooms. Most of edible mushroom species examined until now are selenium-poor (< 1 μ g Se/g dry weight). The fruitbody of some species of wild-grown edible mushrooms is naturally rich in selenium; their occurrence data are reviewed, along with information on their suitability as a dietary source of selenium for humans, the impact of cooking and possible leaching out, the significance of traditional mushroom dishes, and the element's absorption rates and co-occurrence with some potentially problematic elements. The Goat's Foot (Albatrellus pes-caprae) with ~ 200 μ g Se/g dw on average (maximum up to 370 μ g/g dw) is the richest one in this element among the species surveyed. Several other representatives of the genus Albatrellus are also abundant in selenium. Of the most popular edible wild-grown mushrooms, the King Bolete (Boletus edulis) is considered abundant in selenium as well; on average, it contains ~ 20 μ g Se/g dw (maximum up to 70 μ g/g dw). Some species of the genus Boletus, such as B. pinicola, B. aereus, B. aestivalis, B. erythropus, and B. appendiculus, can also accumulate considerable amounts of selenium. Some other relatively rich sources of selenium include the European Pine Cone Lepidella (Amanita strobiliformis), which contains, on average, ~ 20 μ g Se/g dw (up to 37 μ g/g dw); the Macrolepiota spp., with an average range of ~ 5 to < 10 μ g/g dw (an exception is M. rhacodes with < 10 μ g/g dw); and the Lycoperdon spp., with an average of ~ 5 μ g Se/g dw. For several wild-grown species of the genus Agaricus, the selenium content (~ 5 μ g/g dw) is much greater than that from cultivated Champignon Mushroom; these include A. bisporus, A. bitorquis, A. campestris, A. cesarea, A. campestris, A. edulis, A. macrosporus, and A. silvaticus. A particularly rich source of selenium could be obtained from selenium-enriched mushrooms that are cultivated on a substrate fortified with selenium (as inorganic salt or selenized-yeast). The Se-enriched Champignon Mushroom could contain up to 30 or 110 μ g Se/g dw, while the Varnished Polypore (Ganoderma lucidum) could contain up to 72 μ g Se/g dw. An increasingly growing database on chemical forms of selenium of mushrooms indicates that the seleno-compounds identified in carpophore include selenocysteine, selenomethionine, Se-methylselenocysteine, selenite, and several unidentified seleno-compounds; their proportions vary widely. Some aspects of environmental selenium occurrence and human body pharmacokinetics and nutritional needs will also be briefly discussed in this review. 相似文献
70.